GLP-1 수용체 작용제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

GLP-1 Receptor Agonist Market Summary

The global GLP-1 receptor agonist market size was estimated at USD 66.38 billion in 2025 and is projected to reach USD 185.32 billion by 2033, growing at a CAGR of 12.4% from 2026 to 2033. GLP-1 receptor agonists have become an important therapeutic class for managing type 2 diabetes and obesity through mechanisms that enhance insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety.

These combined metabolic effects support glycemic control, sustained weight reduction, and improved cardiometabolic outcomes, increasing their clinical adoption. The rising global prevalence of diabetes and obesity continues to drive demand for advanced treatment options that address multiple disease pathways. The increasing integration of these therapies into clinical practice reflects growing confidence among healthcare providers in their long-term benefits and treatment effectiveness. In 2025, semaglutide received expanded clinical recognition with approval for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis, demonstrating the broadening therapeutic scope of GLP-1 therapies. Such developments highlight the transition of GLP-1 receptor agonists from glucose-lowering agents toward comprehensive metabolic disease management solutions. The growing burden of chronic metabolic disorders is expected to sustain strong market expansion over the coming years.

Pharmaceutical research and development activities remain a major factor supporting innovation in the GLP-1 receptor agonist market, with companies focusing on improved efficacy, convenience, and patient adherence. Advancements in oral drug delivery technologies have created new opportunities to expand patient access beyond injectable therapies. In 2024, Pfizer selected a preferred once-daily modified-release formulation of danuglipron based on pharmacokinetic study results, reflecting continued progress in oral GLP-1 development. Licensing collaborations also strengthened the pipeline, with AstraZeneca partnering for oral GLP-1 candidates targeting obesity and cardiometabolic conditions. These innovations aim to improve treatment adherence by addressing patient preference for oral medications while maintaining therapeutic effectiveness. Expanding clinical pipelines and new formulation technologies are expected to enhance competition and diversify available treatment options. Continued research investment is likely to support future product approvals and broaden the clinical applications of GLP-1 receptor agonists across metabolic disorders.

Growing awareness of chronic disease management and weight-related health risks has increased patient interest in GLP-1 receptor agonist therapies. Educational programs and clinical initiatives have improved understanding of early intervention strategies and long-term management of metabolic health. In 2024, Amylyx Pharmaceuticals advanced the development of Avexitide, a therapy targeting conditions associated with hyperinsulinemic hypoglycemia, with plans for late-stage clinical evaluation beginning in 2025. Digital health programs and disease management platforms have also integrated GLP-1 therapies into structured treatment approaches to improve patient outcomes. Rising consumer awareness of the benefits of weight management has further expanded demand beyond traditional diabetes populations. The availability of newer therapeutic indications and expanding clinical evidence continues to strengthen adoption among both patients and healthcare providers. These factors collectively support the sustained growth of the GLP-1 receptor agonist industry through 2026 and beyond.

Global GLP-1 Receptor Agonist Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 receptor agonist market report based on product, application, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Tirzepatide (Mounjaro, Zepbound)
• Dulaglutide (Trulicity)
• Liraglutide (Victoza, Saxenda)
• Others (Byetta, Bydureon, SOLIQUA)
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Type 2 Diabetes Mellitus
• Obesity / Chronic Weight Management
• Cardiovascular Risk
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Injectable / Parenteral
• Oral
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. GLP-1 Receptor Agonist Market: Product Business Analysis

• 4.1. Product Market Share, 2025 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Semaglutide (Ozempic, Wegovy, Rybelsus)
  • 4.4.1. Semaglutide (Ozempic, Wegovy, Rybelsus) Market, 2021 - 2033 (USD Million)
• 4.5. Tirzepatide (Mounjaro, Zepbound)
  • 4.5.1. Tirzepatide (Mounjaro, Zepbound) Market, 2021 - 2033 (USD Million)
• 4.6. Dulaglutide (Trulicity)
  • 4.6.1. Dulaglutide (Trulicity) Market, 2021 - 2033 (USD Million)
• 4.7. Liraglutide (Victoza, Saxenda)
  • 4.7.1. Liraglutide (Victoza, Saxenda) Market, 2021 - 2033 (USD Million)
• 4.8. Others (Byetta, Bydureon, SOLIQUA)
  • 4.8.1. Others (Byetta, Bydureon, SOLIQUA) Market, 2021 - 2033 (USD Million)

Chapter 5. GLP-1 Receptor Agonist Market: Application Business Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Type 2 Diabetes Mellitus
  • 5.4.1. Type 2 Diabetes Mellitus Market, 2021 - 2033 (USD Million)
• 5.5. Obesity / Chronic Weight Management
  • 5.5.1. Obesity / Chronic Weight Management Market, 2021 - 2033 (USD Million)
• 5.6. Cardiovascular Risk
  • 5.6.1. Cardiovascular Risk Market, 2021 - 2033 (USD Million)

Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Injectable / Parenteral
  • 6.4.1. Injectable / Parenteral Market, 2021 - 2033 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 8.4. North America
  • 8.4.1. North America GLP-1 Receptor Agonist Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait GLP-1 Receptor Agonist Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Eli Lilly and Company
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Sanofi
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Novo Nordisk A/S
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. AstraZeneca
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Teva Pharmaceutical Industries Ltd.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Glenmark Pharmaceuticals
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives